Lymphoma with TNF antagonists
| Etanercept | Infliximab | Adalimumab | |
|---|---|---|---|
| *Rheumatoid arthritis only; | |||
| †majority diffuse large B cells. | |||
| Treated/exposure: | |||
| No of patients | 3389 | 1298* | 2468 |
| Patient-years | (8336) | (2458) | (4870) |
| Total No | 6→9 | 4 | 10 |
| Hodgkin’s/non-Hodgkin’s† | 3/6 | 1/3 | 1/9 |
| Mean time to onset (months), range | 21 (0.1–4.6) | 10–19 (6.4) | 18 (2.0–42.0) |
| SIR lymphoma (95% conf. interval) | 2.31→3.47 (1.59 to 6.59) | 6.4 (1.7 to 16.3) | 5.4 (2.6 to 10.0) |